肝癌合并门静脉癌栓的治疗  

Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus

作　　者：张金岱[1] 陈捷[1] 叶义标[1] 吴潇[1] 陈涛[1] 

机构地区：[1]中山大学孙逸仙纪念医院综合外科,广州510120

出　　处：《岭南现代临床外科》2014年第2期202-206,210,共6页Lingnan Modern Clinics in Surgery

基　　金：广东省医学科学技术基金(编号:B2012101)

摘　　要：门脉癌栓是肝癌患者不良预后的重要指标,然而对于合并门脉癌栓的肝癌患者,国际上并没有统一的治疗标准。尽管临床尝试了各种方法,如肝动脉栓塞化疗(TACE),全身药物的系统治疗,局部消融治疗及积极的手术治疗,但治疗效果不尽理想。随着外科技术的发展以及新的技术和药物的研发,希望通过综合的治疗,提高此类患者的治疗效果,延长患者的生存。Portal vein tumor thrombosis （PVTF） is one of the most important prognostic factors for survival in patients with hepatocellular carcinoma （HCC）. Patients with PVTT have significantly worse outcomes after treatment. There is no consensus about the optimal treatment for such patients. To improve on the results of treatment of HCC with PVTI＇, various methods have been applied, such as transarterial chemoembolization, systematic treatment with drugs, radiofrequency ablation therapy and hepatic resection. However, the results are not so encouraging. With the development of surgical techniques and new drugs, a good prognosis would be achieved with combined treatments.

关 键 词：肝癌 门脉癌栓 治疗方法 

分 类 号：R657.3[医药卫生—外科学]